CSIMarket
 
Collplant Biotechnologies Ltd   (CLGN)
Other Ticker:  
 
 
Price: $5.3501 $-0.38 -6.632%
Day's High: $5.77 Week Perf: -5.78 %
Day's Low: $ 5.14 30 Day Perf: 5.48 %
Volume (M): 36 52 Wk High: $ 13.97
Volume (M$): $ 193 52 Wk Avg: $7.53
Open: $5.54 52 Wk Low: $4.70



 Market Capitalization (Millions $) 59
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 1

Collplant Biotechnologies Ltd


   Company Address: 4 Oppenheimer Rehovot 7670104
   Company Phone Number: 73 232 5600   Stock Exchange / Ticker: NASDAQ CLGN
   CLGN is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Legacy Ventures International Inc

Legacy Ventures International Inc's Exceptional Financial Results in the Medical Equipment and Supplies Industry Indicate Strong Progress



As the July to September 30, 2023 reporting cycle resumes, various corporations, including Legacy Ventures International Inc in the Medical Equipment and Supplies sector, have announced their financial results. In a surprising turn of events, Legacy Ventures International Inc managed to conduct business more economically compared to the previous fiscal quarter, indicating positive signs of progress. This article will delve into the implications of these financial results and explore how they may impact the company going forward.
Improved Operating Deficit:
Legacy Ventures International Inc reported an operating deficit of $-0.006744 million for the July to September 30, 2023 three-month period, which is an improvement from the operating deficit of $-0.009667 million in the same period of the previous year. This significant reduction in operating deficit indicates that the company has been successful in implementing cost-saving measures and enhancing operational efficiency.

Vivos Inc

The company announced sturdy revenue rise, in the third quarter of 2023

Vivos Inc, a leading player in the Medical Equipment and Supplies industry, recently announced its financial results for the fiscal third quarter of 2023. Despite a challenging economic landscape, the company showed resilience by reaching break-even, reporting earnings of $0.00 per share. This is the same as the previous year and the preceding reporting season.
In terms of revenue, Vivos Inc showcased a modest 7.692% growth, generating $0.01 million compared to $0.01 million in the same reporting season a year ago. The sequential revenue growth from the preceding reporting season was also 7.692%. This growth outperforms the Medical Equipment and Supplies sector average of 5.93% in the same period, highlighting Vivos Inc's impressive performance in terms of top-line growth.

Nephros Inc

The company declared epic recent numbers, over the financial period closing Sep 30 2023

For the July to September 30 2023 financial time-frame Nephros Inc decreased a loss per share of $-0.02 per share compare to $-0.31 a year ago and EPS improved from $-0.04 per share from the previous quarter. The revenue jumped by 32.586 % to $3.19 million from $2.41 million in the corresponding quarter a year ago and sequentially revenue surged by 3.735 % from $3.08 million. Medical Equipment and Supplies company's revenue rose faster compared to the the top-line at virtually all of the Medical Equipment and Supplies industry peers, in the third quarter of 2023 the majority entities in Medical Equipment and Supplies sectors made an average revenue improvement of 5.93% relative to the corresponding period a year ago.

Vystar Corporation

Vystar Corporation's Financial Report Reveals Shocking Decline: Stakeholders Left Disappointed



Vystar Corporation, a renowned company in the industry, recently released its financial report for the second quarter of 2023. Unfortunately, the figures have left stakeholders and investors disappointed. The report reveals a substantial decline in revenue, an increase in shortfall per share, and a net deficit compared to the previous year's figures. This article aims to shed light on the financial performance of Vystar Corporation during this period and the potential factors contributing to these disappointing results.
A Dismal Second Quarter
Vystar Corporation's financial performance for the second quarter of 2023 was disastrous. Revenue plunged by an alarming 98.87% to a mere $0.04 million compared to $0.41 million in the same period in the previous year. This sharp decline can be attributed to the company's struggle to maintain demand for its products. Vystar Corporation also experienced a significant increase in shortfall per share, rising from $0.00 to $-0.04.

Non Invasive Monitoring Systems Inc

Non Invasive Monitoring Systems Inc Surprises Investors with Significant Fiscal Improvement, Despite Operating Loss

Investors Analyze Non Invasive Monitoring Systems Inc's Earnings and Future Performance
Experts in the Medical Equipment and Supplies industry are closely examining the fourth quarter earnings report of Non Invasive Monitoring Systems Inc (NIMU). The company reported an operating loss of $-0.033 million for the period between May and July 2023. Notably, the company has not cited any revenue for the same reporting period.
Comparatively, the operating loss for the fourth quarter of 2022 stood at $-0.035 million, serving as a crucial indicator for the overall performance of the company. As NIMU and other ascending corporations in the industry aim to develop their business strategies, the need for cost-effectiveness becomes increasingly important to progress to the next stage.






 

Collplant Biotechnologies Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com